BIM
STOK icon

Bogle Investment Management’s Stoke Therapeutics STOK Stock Holding History

Bogle Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,849
Closed -$362K – 321
2019
Q3 		$362K Buy
+16,849
New +$470K 0.03% 247

Other funds holding STOK

ALSV
ATP Life Science Ventures New York $898M AUM 84.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bogle Investment Management's STOK Position: Q4 2019 in Review

Bogle Investment Management sold out of Stoke Therapeutics (STOK) in Q4 2019, closing a stake of 16,849 shares — an estimated $362K sold.

Bogle Investment Management first reported a position in STOK in Q3 2019 and held it in 1 quarter. The position peaked at $362K in Q3 2019. 64 funds tracked by Wall St. Rank hold STOK as of Q4 2019.

  • Bogle Investment Management reported no remaining Stoke Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Bogle Investment Management sold 16,849 Stoke Therapeutics shares in Q4 2019, an estimated $362K.
  • Bogle Investment Management first reported a position in Stoke Therapeutics in Q3 2019 and held it in 1 quarter.
  • Bogle Investment Management's Stoke Therapeutics position peaked at $362K in Q3 2019.
  • 64 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2019.

Based on Bogle Investment Management's 13F filing for Q4 2019, filed 13 Feb 2020.